The Pharmaceutical Journal
Vol 274 No 7350 p605
21 May 2005

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Letrozole improves survival

Letrozole (Femara) offers a survival benefit over tamoxifen in hormone-sensitive early breast cancer.

A phase III trial involving 8,028 women showed that at a median of 26 months those taking letrozole had a 19 per cent reduced risk of post-surgery recurrence compared with those taking tamoxifen (P=0.003).